Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors alirocumab (Praluent®) and evolocumab (Repatha®) are a new class of LMA drugs for the treatment of familial hypercholesterolemia for patients who did not reach their target LDL on previous combination therapy of statin + ezetimibe and for those intolerant of statins [66]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.